Adaptimmune Therapeutics plc (473A) - Total Liabilities

Latest as of June 2025: €201.59 Million EUR ≈ $235.68 Million USD

Based on the latest financial reports, Adaptimmune Therapeutics plc (473A) has total liabilities worth €201.59 Million EUR (≈ $235.68 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Adaptimmune Therapeutics plc (473A) cash conversion ratio to assess how effectively this company generates cash.

Adaptimmune Therapeutics plc - Total Liabilities Trend (2016–2024)

This chart illustrates how Adaptimmune Therapeutics plc's total liabilities have evolved over time, based on quarterly financial data. Check 473A asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Adaptimmune Therapeutics plc Competitors by Total Liabilities

The table below lists competitors of Adaptimmune Therapeutics plc ranked by their total liabilities.

Company	Country	Total Liabilities
Chian Hsing Forging Industrial Co Ltd TWO:4528	Taiwan	NT$1.46 Billion
Estoril Sol SGPS SA LS:ESON	Portugal	€189.46 Million
Hyungkuk F&B Co Ltd KQ:189980	Korea	₩134.09 Billion
Oceanpal Inc NASDAQ:OP	USA	$4.10 Million
Yuyu Pharma Inc KO:000227	Korea	₩63.32 Billion
Imago Mulia Persada Tbk PT JK:LFLO	Indonesia	Rp89.24 Billion
AXIOS Sustainable Growth NYSE:AXAC	USA	$1.18 Million

Liability Composition Analysis (2016–2024)

This chart breaks down Adaptimmune Therapeutics plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 473A market cap overview.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.52	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-2.84	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	1.54	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Adaptimmune Therapeutics plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Adaptimmune Therapeutics plc (2016–2024)

The table below shows the annual total liabilities of Adaptimmune Therapeutics plc from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	€234.11 Million ≈ $273.70 Million	-3.70%
2023-12-31	€243.10 Million ≈ $284.21 Million	-1.59%
2022-12-31	€247.04 Million ≈ $288.81 Million	-6.28%
2021-12-31	€263.58 Million ≈ $308.16 Million	+139.81%
2020-12-31	€109.92 Million ≈ $128.50 Million	+89.82%
2019-12-31	€57.91 Million ≈ $67.70 Million	+93.98%
2018-12-31	€29.85 Million ≈ $34.90 Million	-61.81%
2017-12-31	€78.16 Million ≈ $91.38 Million	+14.32%
2016-12-31	€68.37 Million ≈ $79.94 Million	--

About Adaptimmune Therapeutics plc

F:473A Germany

Market Cap

$50.20 Million

€42.94 Million EUR

Market Cap Rank

#22444 Global

#1982 in Germany

Share Price

€0.16

Change (1 day)

+6.58%

52-Week Range

€0.03 - €0.41

All Time High

€12.93